Research ArticleArticle
Open Access
Preclinical Metabolism and Disposition of TP0473292, a Novel Oral Prodrug of the Potent Metabotropic Glutamate 2/3 Receptor Antagonist TP0178894 for the Treatment of Depression
Shoko Inatani, Motoki Ochi, Kohnosuke Kinoshita, Jun-ichi Yamaguchi and Hiromi Endo
Drug Metabolism and Disposition May 2023, 51 (5) 572-582; DOI: https://doi.org/10.1124/dmd.122.001116
Shoko Inatani
Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
Motoki Ochi
Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
Kohnosuke Kinoshita
Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
Jun-ichi Yamaguchi
Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
Hiromi Endo
Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Preclinical DMPK of Prodrug for mGlu2/3 Receptor Antagonist
Shoko Inatani, Motoki Ochi, Kohnosuke Kinoshita, Jun-ichi Yamaguchi and Hiromi Endo
Drug Metabolism and Disposition May 1, 2023, 51 (5) 572-582; DOI: https://doi.org/10.1124/dmd.122.001116
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement